Mouse study points to an immune pathway in radiation lung injury
· BehindLines newsroom
A study published in Nature Communications on October 20 examines a possible contributor to lung injury after radiotherapy. In a mouse model, researchers observed changes in the behaviour of certain immune cells. Blocking a signalling pathway reduced injury in that model. The findings remain preclinical and do not demonstrate that a treatment is effective in patients.
Immune cells shift towards a different profile
The team focused on innate lymphoid cells, known as ILCs. In the model described in the paper, targeted irradiation of the left lung was accompanied by a shift from type 2 ILCs towards a more inflammatory type 1 profile. The analyses implicated signalling through type I interferons, particularly interferon beta. Nature Communications
City of Hope, the institution presenting the work, explains the aim as understanding how to protect healthy lung tissue during cancer treatment. Its announcement describes ILC2 cells as helping protect the lung and ILC1 cells as potentially contributing to damaging inflammation. That announcement accompanies the same study; it is not independent confirmation by another research team.
Medical use would require further evidence
The scientific abstract also reports laboratory experiments involving human cells. Stimulation with interferon beta changed the ratio between ILC1 and ILC2 profiles. A response observed in isolated cells does not establish that a medicine would protect the lungs of someone receiving radiotherapy.
In mice, inhibiting type I interferon signalling reduced damage following irradiation. That provides a starting point for a possible therapeutic approach, whose usefulness and safety in humans have yet to be established.
Protecting healthy tissue while preserving the effectiveness of cancer treatment is the underlying objective. The distinction between laboratory findings and patient benefit remains essential: this research alone provides no basis for changing clinical care.